Sanofi SA
Company Profile
Business description
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Contact
46, Avenue de la Great Army
Paris75017
FRAT: +33 153774000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
82,878
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
personal-finance
Can you achieve global diversification with multinational companies?
stocks
Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,826.70 | 48.80 | 0.56% |
CAC 40 | 7,900.03 | 21.57 | 0.27% |
DAX 40 | 24,465.96 | 83.60 | -0.34% |
Dow JONES (US) | 44,714.68 | 256.38 | 0.58% |
FTSE 100 | 8,975.60 | 108.58 | 1.22% |
HKSE | 24,028.37 | 136.05 | 0.57% |
NASDAQ | 20,579.80 | 31.53 | -0.15% |
Nikkei 225 | 39,646.36 | 174.92 | -0.44% |
NZX 50 Index | 12,760.20 | 8.41 | -0.07% |
S&P 500 | 6,274.47 | 11.21 | 0.18% |
S&P/ASX 200 | 8,589.20 | 50.60 | 0.59% |
SSE Composite Index | 3,509.68 | 16.63 | 0.48% |